000			03094cam a2200349 a 4500
003			EG-GiCUC
005			20250223032103.0
008			181020s2018 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.19.05.M.Sc.2018.Ta.O
100	0		_aTarek Ahmed Abdelrehim Ahmed
245	1	0	_aOutcome of refractory/relapsing pediatric hodgkin lymphoma at National Cancer Institute / _cTarek Ahmed Abdelrehim Ahmed ; Supervised Hany Abdelrahman Sayed , Hossam Eldein Ahmed Elzomor , Eman Naguib Elhelaly Khorshed
246	1	5	_aنتائج سرطان الغدد الليمفاوية (هودجكين) المستعصى/المرتد في الأطفال فى المعهد القومى للأورام
260			_aCairo : _bTarek Ahmed Abdelrehim Ahmed , _c2018
300			_a112 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Pediatric Oncology
520			_aPurpose: Hodgkin lymphoma constitutes approximately 7% of childhood cancers. Children and adolescents with Hodgkin lymphoma achieve long-term overall survival rates of over 90% with conventional chemotherapy alone or with a combination of chemotherapy and radiotherapy. Nevertheless, up to 10{u2013}15% of low stage and 20{u2013}25% of children with advanced stage HL will relapse or have primary refractory disease. Our aim is to assess the outcome of children and adolescents with relapsing\refractory Hodgkin Lymphoma at the National Cancer Institute-Cairo University. Methods: This is a retrospective analysis over a 7-year period extending from January 2007 to December 2013, which included all patients with relapsing or primary refractory Hodgkin Lymphoma. Results: Thirty-eight patients were included in this study. Twenty-four patients with relapsing HL and 14 with a primary refractory disease. Overall survival rate was worse for primary refractory than relapsing patients (P value = 0.01). Disease stage at relapse was found to be statistically significant for overall survival rate (P value = 0.03). Extranodal involvement have a worse outcome than nodal disease (P value = 0.02). Three year OS rate was 60.7% while 5-year OS rate was 39.4%. Three year and 5-year EFS was 58.9%. There was a significant difference between patients who responded to salvage chemotherapy after 2 cycles and who responded later regarding event free survival rates (P value = 0.03). The age, gender, pathological subtypes and presence of B symptoms at initial diagnosis or at relapse was not found to be statistically significant
530			_aIssued also as CD
653		4	_aChildhood cancers
653		4	_aHodgkin lymphoma
653		4	_aRefractory / relapsing
700	0		_aEman Naguib Elhelaly Khorshed , _eSupervisor
700	0		_aHany Abdelrahman Sayed , _eSupervisor
700	0		_aHossam Eldein Ahmed Elzomor , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c68082 _d68082